Annalisa Jenkins joins biomarker firm PlaqueTec as CEO

UK-based PlaqueTec has appointed Annalise Jenkins as its chief executive officer, a role that will see her lead the 2018 launch of the biomarker-based liquid biopsy system (LBS).

Dr Jenkins joins the company from Dimension Therapeutics, where she served as its chief executive officer, and her previous roles have seen her gain expertise in scientific research, clinical development, regulatory process and commercialisation.

Jon Moynihan, chairman of PlaqueTec, said: “Dr Jenkins is a passionate and energetic leader with a proven track record of successfully translating exciting science from bench to bedside.

“We are pleased to welcome her to PlaqueTec at an important time for the company, as we will surely benefit from her extensive expertise in growing both private and public companies in the life sciences industry.”

Prior to Dimension Therapeutics, Dr Jenskins served as executive vice president, head of global research and development for Merck Serono and she has also had a nearly 15-year career at Bristol-Myers Squibb.

She said: “I look forward to working with the highly accomplished leadership team and board of directors at PlaqueTec to help advance the study and launch of its pioneering system through increased academic and biopharma collaborations.”